Matthias Schwab (pharmacologist)
Matthias Schwab | |
|---|---|
 | |
| Born | September 3, 1963 |
| Alma mater | |
| Occupation | Pharmacologist |
| Employer | University of Tübingen |
Matthias Schwab (born September 3, 1963 in Nuremberg) is a German doctor and university lecturer. He is director of the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology located on the campus of the Robert-Bosch-Hospital in Stuttgart, an institution of the Robert Bosch Stiftung, and holder of the Chair of Clinical Pharmacology at the University of Tübingen as well as Medical Director of the Department of Clinical Pharmacology at the University Hospital Tübingen.
Life
[edit]After graduating from the Dürer Gymnasium in Nuremberg, Schwab studied Medicine and obtained his doctorate in 1991 at the Institute for Toxicology and Pharmacology at the Friedrich-Alexander University of Erlangen–Nuremberg. After gaining his license to practice medicine, he obtained board qualifications for pediatric and adolescent medicine in 1996 and in clinical pharmacology in 2000.[1]
He completed his habilitation in 2003 at the Eberhard Karls University of Tübingen. After a visiting professorship at the St. Jude Children’s Research Hospital in Memphis (Tennessee, USA) he took over the management of the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and the Chair of Clinical Pharmacology at the University of Tübingen, where he has also been a co-opted professor of the faculty of mathematical and natural science since 2015.[1]
His main research interests focus on pharmacological Genome Research and its importance for Personalized Medicine.[2] He is particularly interested in the application of new technologies in the context of pharmacogenomics including epigenetic[3] aspects in connection with cancer therapies[4] and immunosuppressants
Appointments as full professor for clinical pharmacology at the Medical University of Innsbruck, Austria (2006), as well as professor and chair of clinical pharmacology with simultaneous position as senior physician in the clinic at Karolinska University and Karolinska University Hospital, Sweden (2010), he declined. Since 2018 he is Adjunct Professor of the Departments of Clinical Pharmacology and Biochemistry at Yerevan State Medical University, Armenia.[1]
Scholarships, awards and administrative functions
[edit]- 2024: Honorary Member of the Finnish Society of Clinical Pharmacology[5]
- 2022: Member of the Academia Europaea[6]
- 2022–2025: Member of the Advisory Board of the German Federal Institute for Drugs and Medical Devices (BfArM)[7]
- 2021: Fellow of the British Pharmacological Society (BPS)[8]
- Since 2017 Member of the Ethics Committee of the University Hospital Tuebingen[1]
- 2015/’16/’18/’20/’21/'22/'23/'24: Thomson Reuters/Clarivate Analytics Highly Cited Researchers, rubric “Pharmacology & Toxicology”, and “Cross Field”[9]
- 2016: Robert Pfleger-Research Award[10]
- 2015 and 2018: President of the German Society of Experimental and Clinical Pharmacology and Toxicology (DGPT)[1]
- 2015: Conferment of the Staufer medal in gold by the minister-president of Baden-Württemberg[11]
- Since 2015: Chairman of the Medical Research Commission of the Academy of Sciences and Literature, Mainz[12]
- 2014: Full member of the German National Academy of Sciences Leopoldina[13]
- 2013 – 2018: Chair of the German Society of Clinical Pharmacology (DGKliPha)[1]
- 2012: Full member of the Academy of Sciences and Literature, Mainz[14]
- Since 2008: International Union of Basic and Clinical Pharmacology (IUPHAR): Sub-Committee Pharmacogenetics (2008-2022), Sub-Committee Drug Metabolism and Transporter (2010-2014 Executive Board, 2014-2018 Vice Chair, 2019-2022 Chair); Sub-Committee Pharmacogenetics, Drug Metabolism and Transport (2023–present, Member)[15][16]
- 2010–2017: Member of the governing body of the European Association for Clinical Pharmacology and Therapeutics (EACPT)[1]
- Since 2007: Member of the Drugs Commission of the German Medical Association (AKdÄ)[1]
- 2005: Galenus von Pergamon Award[17]
- 2004: Friedrich Hartmut Dost Award[1]
- Since 2004: full member and deputy chairman of the Commission for Drugs for Children and Young People at the Federal Institute for Drugs and Medical Devices (BfArM), Germany[1]
- Since 2004: Member of the ethics committee of the Medical Association of Baden-Württemberg[1]
Publications (as Editor)
[edit]Journals
[edit]- Since 2007: Editor-in-Chief of Pharmacogenetics & Genomics (with J. Yang, USA)[18]
- Since 2018: Co-Editor in Chief of Drug Research[19]
- Since 2008: Section Editor Pharmacogenomics & Personalized Medicine of Genome Medicine[20]
Monographs
[edit]- Pharmacogenomics in psychiatry. M. Schwab, Wolfgang P. Kaschka, E. Spina. Basel [Switzerland]: Karger. 2010. ISBN 978-3-8055-9499-8. OCLC 655257652.
{{cite book}}: CS1 maint: others (link) - Pediatric clinical pharmacology. Hannsjörg W. Seyberth, Anders Rane, Matthias Schwab. Berlin. 2011. ISBN 978-3-642-20194-3. OCLC 724984111.
{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link) - Pediatric pharmacotherapy. W. Kiess, M. Schwab, Johannes van den Anker. Cham, Switzerland: Springer. 2020. ISBN 978-3-030-50494-6. OCLC 1176512445.
{{cite book}}: CS1 maint: others (link) - Precision Medicine. I. Cascorbi, M. Schwab. Cham, Switzerland: Springer. 2023. ISBN 978-3-031-40046-9. OCLC 1396133889.
{{cite book}}: CS1 maint: others (link)
References
[edit]- ^ a b c d e f g h i j k Curriculum Vitae Matthias Schwab, MD. Website of the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, retrieved August 17, 2022
- ^ „Directory of Members, Matthias Schwab“ Website of the German National Academy of Sciences Leopoldina, retrieved August 17, 2022
- ^ P. Fisel, E. Schaeffeler, M. Schwab: DNA Methylation of ADME Genes. In: Clinical pharmacology and therapeutics. Band 99, Nummer 5, Mai 2016, S. 512–527, doi:10.1002/cpt.343. PMID 27061006 (Review).
- ^ M. Schwab, U. M. Zanger, C. Marx, E. Schaeffeler, K. Klein, J. Dippon, R. Kerb, J. Blievernicht, J. Fischer, U. Hofmann, C. Bokemeyer, M. Eichelbaum: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. In: Journal of clinical oncology. Band 26, Nummer 13, Mai 2008, S. 2131–2138, doi:10.1200/JCO.2006.10.4182. PMID 18299612.
- ^ Finnish Society of Clinical Pharmacology
- ^ Elected Members 2022, Matthias Schwab
- ^ Advisory Board of the BfArM
- ^ Fellows' Directory
- ^ Clarivate Web of Science
- ^ Michael Herm (2016-06-20). "Medizinische Spitzenforschung – IKP Leiter Prof. Dr. Matthias Schwab erhält Robert Pfleger-Preis". Idw-online.de. Retrieved 2016-09-16.
- ^ Pressemitteilung Staatsministerium, 2. Februar 2016
- ^ Members of the Medical Research Commission
- ^ List of Members
- ^ Members of the Academy, Retrieved August 18, 2022
- ^ Drug Metabolism & Transport > Governance
- ^ Pharmacogenetics/Genomics > Governance
- ^ Zelltod durch Genvariante. In: Ärzte Zeitung. 16. November 2005
- ^ "Editorial Board : Pharmacogenetics and Genomics". journals.lww.com. Retrieved 2022-09-21.
- ^ "Editorial Board - Drug Research - Georg Thieme Verlag". Thieme (in German). Retrieved 2022-09-21.
- ^ "Genome Medicine". BioMed Central. Retrieved 2022-09-21.
| International | |
|---|---|
| National | |
| Academics | |
| People | |
| Other | |
- 1963 births
- Living people
- Academic staff of the University of Tübingen
- 20th-century German physicians
- University of Erlangen-Nuremberg alumni
- Scientists from Nuremberg
- German pharmacologists
- Physicians from Bavaria
- 21st-century German physicians
- Members of Academia Europaea
- Fellows of the British Pharmacological Society
- Members of the German National Academy of Sciences Leopoldina